Plus therapeutics expands strategic agreement with telix isotherapeutics group for rhenium-186 radioisotope supply

Austin, texas, dec. 03, 2024 (globe newswire) -- plus therapeutics , inc. (nasdaq: pstv), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its master services agreement (msa) with telix isotherapeutics group inc. (‘isotherapeutics', a telix group company). this msa secures a reliable supply of cgmp re-186, the radioisotope used in plus therapeutics' lead radiotherapeutic candidate rhenium (186re) obisbemeda.
PSTV Ratings Summary
PSTV Quant Ranking